Is Retatrutide Legal? FDA Status, Compounding and Red Flags (2026)

Retatrutide is the most talked-about weight-loss injection that you cannot legally get from a pharmacy. Online sellers and a few clinic menus offer it anyway, often next to semaglutide and tirzepatide, as if it were the next product in the same family. It is not. This page covers what retatrutide is, what the FDA has actually said, and how to read an offer for it.

What it is

Retatrutide (Eli Lilly code LY3437943) is an investigational once-weekly injection that targets three hormone receptors at once: GIP, GLP-1 and glucagon. Semaglutide targets one of those and tirzepatide two. Lilly is running it through clinical trials. ClinicalTrials.gov lists 14 Phase 3 studies for retatrutide as of October 21, 2026, and many earlier studies are already marked completed, including some with completion dates in 2026.

Completed trials are not an approval. As of this writing, the openFDA Drugs@FDA database returns no record for retatrutide, so there is no approved retatrutide product from any manufacturer.

The FDA status, in order

No approval. FDA’s page on unapproved GLP-1 drugs (content current as of October 1, 2026) states that retatrutide “cannot be used in compounding under federal law” and that it is not a component of an FDA-approved drug and has not been found safe and effective for any condition.

Why compounding does not apply. The FDA’s September 9, 2025 warning letter to ASN-Labs lays out the logic. Under section 503A, a pharmacy can compound with a bulk substance only if it has a USP/NF monograph, is a component of an approved drug, or is on the 503A bulks list. The letter says retatrutide meets none of those tests. For outsourcing facilities under section 503B, it is not on the 503B bulks list and is not on the drug shortage list. The result, in the FDA’s words, is that such products are “unapproved new drugs and misbranded drugs.”

Who the FDA has warned. The same FDA page says the agency has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers. It has also warned API distributors for selling retatrutide to compounders, and outsourcing facilities for repackaging it.

The “research use” defense. The FDA has also warned companies that sell semaglutide, tirzepatide, retatrutide, survodutide or mazdutide labeled “for research purposes” or “not for human consumption” while selling them directly to consumers with dosing instructions. The agency urges consumers not to buy them. We cover this in detail in our guide to research-use-only peptides.

A listing is not an approval. NLM’s DailyMed database returns 10 labeling entries for “retatrutide,” all published November 17, 2025 by a single overseas e-commerce company. DailyMed accepts labeling submissions from firms regardless of approval status, so a DailyMed entry does not mean the FDA approved the drug. Treat a seller who points to one as a red flag.

Why this is not the same as semaglutide

Compounded semaglutide and tirzepatide existed under a specific legal pathway, tied to the FDA’s shortage listings, and that pathway has narrowed (see our pages on semaglutide and tirzepatide). Retatrutide never had that pathway. There is no shortage, no approved product to compound from, and no bulks-list entry. The FDA has not framed it as a gray area.

Red flags we check for

Retatrutide on a clinic menu or telehealth checkout. Under the FDA’s position, any offer to dispense it to patients is an offer of an unapproved drug. It is one of the criteria that keeps a clinic out of this directory.

“Same as the next Lilly drug” claims. The ASN-Labs letter also cites claims that a compounded product has “the same active ingredient” as an approved drug as false or misleading. Compounded products are not FDA-approved.

Vials sold with dosing charts. Research-labeled vials with reconstitution and dosing instructions are the pattern the FDA describes as sold for human use.

No named, NPI-verified prescriber. A real clinical relationship comes first. If nobody can say who prescribes and under what rationale, the “medical” framing is not real.

Trial-participant language. Joining an actual clinical trial runs through the sponsor and ClinicalTrials.gov, not a clinic menu.

What we found in the directory

We evaluated 80 clinics and excluded 41. Our six verified clinics are the ones that cleared the NPI, licensing and sourcing checks. None of them lists retatrutide in our dataset. Check any offer against that standard, and ask any clinic directly what it dispenses, from which pharmacy, and under whose license.

Browse our verified clinics in Houston, read what disqualifies a clinic and why, and see our full verification standard.

---

Sources: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”, content current as of October 1, 2026, retrieved October 21, 2026. FDA, Warning Letter to ASN-Labs (716459), September 9, 2025, retrieved October 21, 2026. FDA, 503A Bulk Drug Substances list (retatrutide not present) and Category 2 list (retatrutide not present), retrieved October 21, 2026. FDA Drugs@FDA via openFDA (api.fda.gov/drug/drugsfda.json, generic name retatrutide: no matches), retrieved October 21, 2026. NLM DailyMed API (spls.json?drug_name=retatrutide, 10 results), retrieved October 21, 2026. ClinicalTrials.gov API v2 (query term “retatrutide”), retrieved October 21, 2026.

This article is independent editorial content, not medical advice. See our medical disclaimer.